retatrutide peptide eli lilly Lilly, with new data, to seek FDA approval of obesity drug Retatrutide: The New Triple-Agonist Weight

Mol Metab 78:101817 Huang KP et al (2024) Dissociable hindbrain GLP1R circuits for satiety and aversion

Frozen tissues were cut into 5-m-thick sections using a Cryostat Microm HM 560 (Thermo Fisher Scientific) at 30 C

The terms state that cancellation should be submitted at least 48 hours before the monthly processing date to prevent another charge

The balanced plate works because it controls for two things at once: the calorie density of what you eat (vegetables are low in energy, protein and carbohydrates are moderate, fats are high) and the balance of macronutrients (protein, fat, and fibre help you feel fuller for longer)

[5] [2] Patients starting GLP-1 therapy should be aware of: Potential mood changes during the adjustment period, particularly if experiencing significant gastrointestinal side effects The importance of continuing existing mental health treatments unless advised otherwise by their healthcare team Realistic expectations regarding weight loss and metabolic improvements, as unrealistic goals can lead to disappointment Healthcare professionals prescribing GLP-1 agonists should: Screen for depression and anxiety at baseline and during follow-up appointments Monitor for mood changes , particularly in patients with pre-existing mental health conditions Ensure coordinated care between diabetes/obesity services and mental health teams when appropriate It is essential to recognise that GLP-1 agonists are not a substitute for evidence-based depression treatments, including psychological therapies and antidepressant medications when indicated

Kang S, Barnhill RL, Mihm MC Jr, Sober AJ